A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer

This study tests a new drug called BNT327 — an investigational immunotherapy — combined with standard chemotherapy as a first-line treatment for people with metastatic pancreatic cancer (cancer that has spread beyond the pancreas). The study evaluates how safe and effective this combination is. **You may be eligible if...** - You have been confirmed to have metastatic pancreatic ductal adenocarcinoma (the most common type of pancreatic cancer) - You have not yet received treatment for your metastatic disease - You are able to provide a tumor tissue sample - You meet performance and organ function requirements **You may NOT be eligible if...** - Your cancer is localized (has not spread) - You have active autoimmune disease - You have received prior systemic treatment for metastatic disease - You have significant heart, liver, or lung problems Talk to your doctor to see if this trial is right for you.